Biohaven (BHVN) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Xeris Biopharma (XERS) has outperformed Biohaven (BHVN) over the past year, gaining 28.0% versus a loss of 29.9%. Xeris Biopharma is the larger company by market cap ($1.91 billion vs $1.82 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHVN | XERS |
|---|---|---|
| Share price | $12.08 | $10.48 |
| Market cap | $1.82B | $1.91B |
| 1-day change | +1.26% | +2.85% |
| YTD return | +7.00% | +33.50% |
| 1-year return | -29.89% | +27.96% |
| 5-year return | — | +424.00% |
| Forward P/E | — | 28.32 |
| EPS (TTM) | $-4.62 | $-0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $291.85M |
| Revenue growth (YoY) | — | +43.72% |
| Net income (latest FY) | $-738.82M | $554.00K |
| Gross margin | — | 85.41% |
| Operating margin | — | 8.53% |
| Net margin | — | 0.19% |
| 52-week high | $18.57 | $11.33 |
| 52-week low | $7.48 | $5.25 |
| Distance from 52-week high | -34.93% | -7.50% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +76.08% | +22.71% |
| Average volume | 2.61M | 2.19M |
| Shares outstanding | 151.04M | 182.32M |
| Employees | 274 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XERS has outperformed BHVN by 57.9 percentage points over the past year.
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
BHVN vs XERS FAQ
Which is bigger, Biohaven or Xeris Biopharma?
Xeris Biopharma (XERS) is larger, with a market capitalization of $1.91B compared with $1.82B for Biohaven (BHVN).
Which stock has performed better over the past year, BHVN or XERS?
XERS returned +27.96% over the past 12 months, compared with -29.89% for BHVN (price return, excluding dividends). Past performance does not predict future results.
Are Biohaven and Xeris Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.